Physician profile
Christopher Devries
NPI 1578083291
$1,284.51
in general payments reported to CMS, 2019-2025
26 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2022: $301 · 2023: $436 · 2024: $271 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $172.78 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Bayer Healthcare Pharmaceuticals INC. | $151.33 | 2022-2025 | |
| Abbvie INC. | $135.67 | 2019-2024 | Lo Loestrin Fe |
| Astellas Pharma US INC | $76.95 | 2023 | Veozah |
| Exeltis, USA INC. | $75.27 | 2022-2024 | Slynd |
| Organon LLC | $71.78 | 2022-2024 | Nexplanon |
| Sage Therapeutics, LLC | $67.93 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $61.54 | 2022 | |
| Merck Sharp & Dohme LLC | $49.52 | 2022-2024 | Gardasil 9, Gardasil |
| Gynesonics, INC. | $47.18 | 2022-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Sumitomo Pharma America, INC. | $46.05 | 2023 | Myfembree |
| Pfizer INC. | $45.96 | 2023 | |
| Ibsa Pharma INC. | $31.83 | 2022 | |
| Shield Therapeutics INC | $22.75 | 2024 | |
| Therapeuticsmd, INC. | $22.57 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.07 | 2019 | |
| Medicem INC. | $21.87 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.31 | 2025 | Qelbree |
| C. R. Bard, INC. & Subsidiaries | $20.10 | 2023 | Bd Onclarity |
| Meditrina | $19.77 | 2024 | |
| Coloplast Corp | $18.79 | 2023 | Saffron |
| Boston Scientific Corporation | $17.36 | 2019 | |
| Exact Sciences Corporation | $16.52 | 2023 | Cologuard Collection Kit |
| Novo Nordisk INC | $16.06 | 2023 | Wegovy |
| Daiichi Sankyo INC. | $15.96 | 2023 | Injectafer |
| Baxter Healthcare | $15.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Devries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.